Navigation Links
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor

BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.

Dr. Hidvegi stated from his office in Budapest, Hungary:

"The Biropharma claim that research on Avemar does not apply to AveULTRA,, is misleading. Avemar has always been manufactured according to methods which I developed and patented. American BioSciences utilizes processes covered by my most recent pending patent. State of the art technology more precisely controls process times and temperatures creating a better quality fermented wheat germ extract. Independent analysis shows that Avemar made by Biropharma and sold under the brand name Ave(TM) and Avemar made by American BioSciences and sold under the brand name AveULTRA, are virtually identical, confirmed by the technique of HPLC finger printing. Furthermore, independent comparison by biological assays in both cell lines and animal models shows the American BioSciences product has superior effects," he said. According to Dr. Hidvegi, these data are being prepared for publication in a peer-reviewed scientific journal.

AveULTRA, newly introduced by American BioSciences, contains the same amount of Avemar fermented wheat germ actives per daily use packet as Ave and is three times more concentrated, with 99 percent less non-active ingredients and no sugar. AveULTRA supports cell metabolic regulation, promotes immune system modulation, and maintains healthy cellular and humoral (Th1/Th2) immune balance. It promotes optimal NK cell targeting ability and the coordinated response of macrophages, B-cells and T-Cells.

"AveULTRA is a huge improvement over the original Ave," said Cincinnati OB/GYN Maureen Pelletier, MD, CCN. "My patients like the concentrated formula, as well as the improved taste."

For more information, contact Dean Draznin Communications, Inc.

SOURCE American BioSciences

SOURCE American BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
2. Viron to Present Data from Phase II Trial at American Heart Association Conference
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. American Oriental Bioengineering Announces September Investor Conferences Participation
9. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):